Promoted Content Promoted Content

X

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Neurology Drugs in Phase III Clinical Development in KOREA, REPUBLIC OF

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              GNT Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              GNT Pharma Announces Positive Top-Line Results in a Phase II Study of Nelonemdaz for Acute Ischemic Stroke Patients Treated With Endovascula...

              Contact the Supplier

              Lead Product(s): Nelonemdaz

              Therapeutic Area: Neurology Product Name: Neu2000KWL

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2020

              Details:

              In this study, the addition of nelonemdaz to surgical blood clot removal improved a patient’s chances of returning to functional independence 90 days later.

              GNT Pharma

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              KOREA, REPUBLIC OF Korea, Republic Of

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              CPhI North America Online

              Participation Not Confirmed

              Update your events

              GNT Pharma's Anti-dementia Drug 'crisdesalazine' Demonstrates Efficacy in Phase III Clinical Study with Companion Dogs with Dementia

              Contact the Supplier

              Lead Product(s): Crisdesalazine

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 14, 2020

              Details:

              Crisdesalazine demonstrated significant improvement in cognition function in the primary outcome measure

              PharmaCompass__DigitalAd